



Anatara Lifesciences is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need

Fast Facts

ASX Code: ANR

Market Capitalisation¹: \$24.7 million

Share Price¹: \$0.50

Current Cash²: \$6.0 million

Ordinary Shares: 49,413,236

Options: 2,346,000

Board of Directors:

Sue MacLeman

Dr Jane Ryan

Dr Tracie Ramsdale

Dr David Brookes

Management:

Steve Lydeamore, CEO

Dr Tracey Brown, CSO

Dr Michael West, COO

Product Development

Advisory Board:

Prof Peter Gibson

Dr Rebecca Burgell

Dr Jakob Begun

Prof Barry Campbell

Assoc Prof Simon Keely

Corporate Highlights

- Strong initial human gastrointestinal health product - Gastrointestinal ReProgramming (GaRP) dietary supplement - aimed at restoring and maintaining gut health
- GaRP will target the significant unmet market need for complementary medicines in gastrointestinal health
- Successful *in vitro* GaRP proof of concept studies
- Anatara has the funds necessary to progress the first human product through to anticipated partnering in 2020.
- Exclusive global licensing agreement with leading animal health company Zoetis, for the worldwide development, manufacture, distribution and marketing of Detach in livestock and horses
- Detach approved for use in piglets by Australian Pesticides and Veterinary Medicines Authority (APVMA)



Bringing Science
to Supplements

¹ As at 11 February 2019, ² Appendix 4C - 31 December 2018 (\$1.5m cash, \$4.5m deposits with terms greater than 90days)



Introducing Gastrointestinal ReProgramming (GaRP) Dietary Supplement

Anatara's **Gastrointestinal ReProgramming (GaRP)** dietary supplement is a proprietary formulation that combines bromelain with other evidence-based ingredients to manage the symptoms associated with **human gastrointestinal conditions** such as IBS and IBD.

Designed to be used as a sole therapy or as an adjunct therapy in combination with current IBD and IBS prescription medications, GaRP is a **dietary supplement** that will empower patients to better manage their chronic conditions.




Human Health Focus

Anatara has developed a new product aimed at restoring and maintaining a healthy gut and microbiome, and managing the symptoms associated with gastrointestinal conditions such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

Anatara's focus on this opportunity was based on market potential, competitive advantage, quality of supporting data, strength of intellectual property protection and speed to market.

How does it work?

GaRP is a microbiome targeted dietary supplement, aimed at:



³ GRAS = Generally Recognised As Safe - US FDA designation that a substance is considered safe for use in food

Market Opportunity

Irritable Bowel Syndrome (IBS)

Affects around **11%** of the global population⁴

~50% of patients⁵ turn to dietary supplements and complementary medicines

Low grade inflammation



Inflammatory Bowel Disease (IBD)

>5 million sufferers globally⁶

30-50% of IBD patients⁷ turn to complementary and alternative medicines

Chronic inflammation



Shared disease characteristics:

- Altered microbiome
- Impaired intestinal barrier function
- Mucosal damage

The Facts

Irritable Bowel Syndrome (IBS)

US\$25b GI and digestive health nutraceuticals market in 2016⁸

US\$36b / CAGR 8%
By 2021⁸

IBS is the most commonly diagnosed gastrointestinal condition and a significant health care burden⁹

Inflammatory Bowel Disease (IBD)

Chronic Life-long Disease Affects women and men equally

Most commonly diagnosed in young adults⁶ 15-35 years of age

IBD is a global disease with accelerating incidence in newly industrialised countries¹⁰

Successful Proof of Concept Studies



- Potential breakthrough dietary product
 - Anatar's proprietary GaRP formulation was efficacious* and:
 - ✓ Reduced production of pro-inflammatory proteins by gut and inflammatory cells by >85%;
 - ✓ Reduced the attachment and invasion of IBD and IBS pro-inflammatory bacteria into healthy gut cells by >95%;
 - ✓ Protected and maintained gut integrity.
- * Demonstrated using industry-standard *in vitro* gut models

⁴ Clinical Gastroenterology and Hepatology 2012; 10, 712-721, ⁵ World J. Gastroenterol 2014; 346-362, ⁶ Crohn's and Colitis Australia, ⁷ Gastroenterology 2017; 152:415-429,

⁸ Nutraceuticals: Global Markets, BCC, Research March 2017, ⁹ Clin Colon Rectal Surg. 2012 Mar; 25(1): 46-52, ¹⁰ Lancet. 2018 Dec 23;390(10114):2769-2778



Anatara Lifesciences Ltd (ASX:ANR) Summary

- Innovative, evidence-based products, backed by scientific and clinical studies for gastrointestinal health
- GaRP dietary supplement seeks to target IBS and IBD patients
- Patentable multi-component, dual-targeted formulation
- Delivers the components where they can be most effective
- Board and management have significant human health deal experience
- 18 – 24 months to partnering milestone

Advantages of dietary supplements:

- ✓ Fewer regulatory requirements than pharmaceuticals
- ✓ Lower development costs
- ✓ Lower development risk
- ✓ Faster time to market
- ✓ Rapid market penetration
- ✓ Are understood by the public and health professionals

Clear Path to Commercialisation

	2017 H1	2017 H2	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2
Confirmed GRAS status for components with FDA	✓							
Established collaboration with University of Liverpool (UK)		✓						
Completed product development plan		✓						
Patent Application filed				✓				
Commercial feasibility			✓					
Manufacturing - sourced suppliers		✓						
Proof of concept				✓				
Animal study (IBD)						F*		
Human observational study (IBS)						S*		
Partnering discussions								F*

* Finish; Start

Keep in touch

Steven Lydeamore, CEO



@AnataraANR

slydeamore@anatara.com

www.anataralifesciences.com

Sign up for Email Alerts

<https://anataralifesciences.com/contact/email-alerts/>



ANATARA LIFESCIENCES

